{"DataElement":{"publicId":"2603190","version":"1","preferredName":"Patient Chemotherapy Personal Medical History Platinum-Based Taxane Compound Therapeutic Procedure Ind-2","preferredDefinition":"the yes/no indicator whether the patient's personal medical history, an account of all medical events and problems a person has experienced, including a prior platinum-based or taxane-based therapy, anticancer drugs that inhibit cancer cell growth by stopping cell division, to produce an effect that is intended to alter the course of a pathologic proces.","longName":"PT_PL_TAX_TX_PMH_IND","context":"CTEP","contextVersion":"2.31","DataElementConcept":{"publicId":"2603154","version":"1","preferredName":"Patient Chemotherapy Personal Medical History Platinum-Based Taxane Compound Therapeutic Procedure","preferredDefinition":"information related to a patient's personal medical history, an account of all medical events and problems a person has experienced, including a prior platinum-based or taxane-based therapy, anticancer drugs that inhibit cancer cell growth by stopping cell division, to produce an effect that is intended to alter the course of a pathologic proces.","longName":"PT_PLAT_TAX_TX_PMH","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2233604","version":"1","preferredName":"Patient","preferredDefinition":"A person who requires medical care.","longName":"C16960","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Patient","conceptCode":"C16960","definition":"A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F95D94B9-D847-2792-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-13","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-06-13","modifiedBy":"ONEDATA","dateModified":"2005-06-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2603152","version":"1","preferredName":"Platinum-Based Taxane Compound Therapeutic Procedure Personal Medical History","preferredDefinition":"Derived from or containing platinum.:Anticancer drugs that inhibit cancer cell growth by stopping cell division. Also called antimitotic or antimicrotubule agents or mitotic inhibitors.:An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process.:an account of all medical events and problems a person has experienced.","longName":"C25620:C1490:C49236:C18772","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Platinum-Based","conceptCode":"C25620","definition":"Derived from or containing platinum.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Taxane Compound","conceptCode":"C1490","definition":"A type of drug that blocks cell growth by stopping mitosis (cell division). Taxanes interfere with microtubules (cellular structures that help move chromosomes during mitosis). They are used to treat cancer. A taxane is a type of mitotic inhibitor and a type of antimicrotubule agent.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Therapeutic Procedure","conceptCode":"C49236","definition":"An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Personal Medical History","conceptCode":"C18772","definition":"A record of a patient's background regarding health and the occurrence of disease events of the individual. In addition, personal medical history may be a variable in epidemiologic studies.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2A6472AA-8F6C-14B6-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-26","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-02-26","modifiedBy":"ONEDATA","dateModified":"2007-02-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008551","version":"1","preferredName":"Assessments","preferredDefinition":"evaluations of the patient and the patient's disease.","longName":"ASSESS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22DA727-6718-5A2D-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2A647324-BDF3-14D1-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-26","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-02-26","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3506068","version":"1","preferredName":"Yes No Indicator","preferredDefinition":"The preferred Value Domain to indicate a question with permissible values of yes/no.","longName":"YES_NO_IND","context":"NCI Standards","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":"2","maxLength":"3","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"No","valueDescription":"No","ValueMeaning":{"publicId":"3197154","version":"1","preferredName":"No","longName":"3197154","preferredDefinition":"The non-affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D865DE5-55AD-1AC9-E040-BB89AD436B4F","latestVersionIndicator":"Yes","beginDate":"2011-03-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-03-02","modifiedBy":"SOKKERL","dateModified":"2023-12-05","changeDescription":null,"administrativeNotes":"2022.12.28 Alt VM added per ticket request CADSR0001837. aj","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C37A1BEB-75C2-B6C9-E040-BB89AD434179","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"ONEDATA","dateModified":"2012-06-27","deletedIndicator":"No"},{"value":"Yes","valueDescription":"Yes","ValueMeaning":{"publicId":"3197153","version":"1","preferredName":"Yes","longName":"3197153v1.00","preferredDefinition":"The affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes","conceptCode":"C49488","definition":"The affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D865DE5-558A-1AC9-E040-BB89AD436B4F","latestVersionIndicator":"Yes","beginDate":"2011-03-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-03-02","modifiedBy":"SOKKERL","dateModified":"2023-12-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C37A1BEB-75CC-B6C9-E040-BB89AD434179","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"ONEDATA","dateModified":"2012-06-27","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"3502157","version":"1","preferredName":"Yes No Indicator Value Domains","preferredDefinition":"Conceptual domain that includes value meanings to be used for Indicator Value Meanings such as Yes, No, Unknown, No Applicable","longName":"YES_NO_IND_VD","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C377DE0C-8C3E-DCA8-E040-BB89AD431B6D","latestVersionIndicator":"Yes","beginDate":"2012-06-27","endDate":null,"createdBy":"CURTIST","dateCreated":"2012-06-27","modifiedBy":"CURTIST","dateModified":"2012-06-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2421125","version":"1","preferredName":"Ind-2","preferredDefinition":"A caDSR representation term that is used to indicate a question with permissible values of yes/no","longName":"C38147","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes or No Response","conceptCode":"C38147","definition":"A response or indicator that can have a value of either yes or no.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RETIRED ARCHIVED","registrationStatus":"Retired","id":"0303DF01-F4B4-15EC-E044-0003BA3F9857","latestVersionIndicator":"No","beginDate":"2005-10-18","endDate":"2016-04-27","createdBy":"SHIDED","dateCreated":"2005-10-18","modifiedBy":"TAYLORT","dateModified":"2020-10-03","changeDescription":"10.3.20 TL changed WFS from RETIRED PHASED OUT to RETIRED ARCHIVED. Changed Workflow Status DBW 04-27-2016","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Standard","id":"C37A1BEB-75AE-B6C9-E040-BB89AD434179","latestVersionIndicator":"Yes","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"TSESU","dateModified":"2023-08-16","changeDescription":"8/29/17 tt added CSI per Round 5 finalization task. 3/12/17 jk added Standard reg status; ownership transfered from CTEP to NCI Standards with concurrence of CTEP/Brian Campbell. jk","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2961451","version":"1","longName":"Children's Oncology Group (COG)","context":"COG","ClassificationSchemeItems":[{"publicId":"2961452","version":"1","longName":"Statistics and Data Center","context":"COG"}]},{"publicId":"4057943","version":"1","longName":"Disease Site","context":"NRG","ClassificationSchemeItems":[{"publicId":"10000078","version":"1","longName":"GOG-0186H","context":"NRG"},{"publicId":"10000077","version":"1","longName":"GOG-0186H","context":"NRG"},{"publicId":"4104904","version":"1","longName":"GOG-0186H","context":"NRG"},{"publicId":"10000081","version":"1","longName":"GOG-0186J","context":"NRG"},{"publicId":"4104906","version":"1","longName":"GOG-0186J","context":"NRG"},{"publicId":"10000082","version":"1","longName":"GOG-0186J","context":"NRG"},{"publicId":"10000346","version":"1","longName":"GOG-0186K","context":"NRG"},{"publicId":"10000345","version":"1","longName":"GOG-0186K","context":"NRG"},{"publicId":"4104907","version":"1","longName":"GOG-0186K","context":"NRG"}]}],"AlternateNames":[{"name":"NRG","type":"USED_BY","context":"NRG"},{"name":"PT_PL_TAX_TX_PMH_IND","type":"USED_BY","context":"NRG"},{"name":"COG","type":"USED_BY","context":"COG"}],"ReferenceDocuments":[{"name":"Prior platinum based and/or p","type":"Preferred Question Text","description":"Prior platinum based and/or paclitaxel based therapy","url":null,"context":"CTEP"},{"name":"CRF Text2","type":"Alternate Question Text","description":"Has the patient had previous therapy with anthracyclines, taxanes, or trastuzumab for any malignancy?","url":null,"context":"CTEP"},{"name":"CRF Text1","type":"Alternate Question Text","description":"Prior allergic reaction to carboplatin, cisplatin or paclitaxel","url":null,"context":"CTEP"},{"name":"CRF Text4","type":"Alternate Question Text","description":"Has the patient had previous treatment with weekly paclitaxel for recurrent or persistent disease?","url":null,"context":"CTEP"},{"name":"CRF Text5","type":"Alternate Question Text","description":"Has the patient had previous therapy with anthracyclines or taxanes for any malignancy?","url":null,"context":"CTEP"},{"name":"CRF Text7","type":"Alternate Question Text","description":"Has the patient received weekly Paclitaxel for recurrent or persistent disease?","url":null,"context":"CTEP"},{"name":"CRF Text 6","type":"Alternate Question Text","description":"Did the patient complete a course of standard neoadjuvant chemotherapy consisting of an anthracycline and/or taxane-based regimen","url":null,"context":"CTEP"},{"name":"CRF Text 8","type":"Alternate Question Text","description":"Did the patient receive a minimum of 12 weeks of standard neoadjuvant chemotherapy consisting of an anthracycline and/or taxane-based regimen?","url":null,"context":"CTEP"},{"name":"CRF Text 9","type":"Alternate Question Text","description":"Did the patient have previous therapy with anthracyclines, taxanes, carboplatin, trastuzumab, or other HER2 targeted therapies for any malignancy","url":null,"context":"CTEP"},{"name":"CRF Text 10","type":"Alternate Question Text","description":"Did the patient complete at least 6 cycles of neoadjuvant or adjuvant chemotherapy containing anthracyclines, taxanes, or the combination of both","url":null,"context":"NRG"},{"name":"CRF Text 11","type":"Alternate Question Text","description":"Did the patient have any previous therapy with anthracyclines or taxanes for any malignancy","url":null,"context":"CTEP"},{"name":"CRF Text12","type":"Alternate Question Text","description":"Did the patient receive a minimum of 8 weeks of standard neoadjuvant chemotherapy consisting of an anthracycline and/or taxane-based regimen?","url":null,"context":"CTEP"},{"name":"COG_CRF_Text_1","type":"Alternate Question Text","description":"Did patient previously receive treatment on AOST0331 or CCG7921 (also known as INT0133 and POG9351) OR did patient receive upfront therapies, which included cisplatin, with or without ifosfamide?","url":null,"context":"COG"},{"name":"CRF Text 13","type":"Alternate Question Text","description":"Has the patient received prior carboplatin/gemcitabine or cisplatin/gemcitabine?","url":null,"context":"NRG"},{"name":"CRF Text 14","type":"Alternate Question Text","description":"Has the patient received prior weekly paclitaxel in a platinum-resistant setting?","url":null,"context":"NRG"}],"origin":"RTOG CRF:Radiation Therapy Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"2A650BAD-3EBD-236D-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-26","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-02-26","modifiedBy":"TYRRELLM","dateModified":"2023-12-20","changeDescription":"Replaced VD Therapy Ind-2 2018279v1 with VD ID#3506068 - Yes No Indicator - dbw","administrativeNotes":"12.20.2023 Added AQT per request ticket CADSR0003202_mmt","unresolvedIssues":null,"deletedIndicator":"No"}}